Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Clinical trial NCT01805557 · COMPLETED
Trial details
- NCT number
- NCT01805557
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-02-04
- Primary completion
- 2019-03-12
- Enrollment
- 108
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.